TROPHY Study Confirms Cardesartan Cilexetil Reduces Risk of Hypertension.Tokyo, Japan, Mar 17, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical recently announced that the results of the TROPHY (Trial of Preventing Hypertension hypertension or high blood pressure, elevated blood pressure resulting from an increase in the amount of blood pumped by the heart or from increased resistance to the flow of blood through the small arterial blood vessels (arterioles). ) study were published in the March 14 issue of the online version of the New England Journal of Medicine The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. . The TROPHY study, which covered 772 people with prehypertension in the US, evaluated how cardesartan cilexetil affects the incidence of hypertension. The study results indicate that the risk of hypertension was significantly lowered in the group administered with cardersartan cilexetil, as compared with the placebo placebo (pləsē`bō), inert substance given instead of a potent drug. Placebo medications are sometimes prescribed when a drug is not really needed or when one would not be appropriate because they make patients feel well taken care of. group. Cardersartan cilexetil is currently available in Japan under the trade name of Blopress. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion